Acrivon Therapeutics (ACRV) Accumulated Expenses (2021 - 2026)

Acrivon Therapeutics (ACRV) has reported Accumulated Expenses for 6 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 1.92% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (up 1.92% YoY), while the FY2025 annual figure was $12.2 million, up 123.88% from the prior year.
• Accumulated Expenses retreated to $2.2 million in Q1 2026 per ACRV's latest filing, from $12.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $12.3 million in Q3 2024 and bottomed at $1.3 million in Q3 2022.
• Historically, Accumulated Expenses has averaged $5.2 million across 5 years, with a median of $3.9 million in 2023.
• Annual changes were most pronounced in 2024 — Accumulated Expenses soared 308.15% — and 2025, when it slumped 64.72%.
• Acrivon Therapeutics' Accumulated Expenses stood at $4.9 million in 2022, then declined by 21.0% to $3.9 million in 2023, then soared by 41.35% to $5.5 million in 2024, then soared by 123.88% to $12.2 million in 2025, then sank by 82.22% to $2.2 million in 2026.
• Business Quant data shows ACRV's Accumulated Expenses at $2.2 million in Q1 2026, $12.2 million in Q4 2025, and $4.4 million in Q3 2025.